Correlation Between Molecular Partners and Newron Pharmaceuticals
Can any of the company-specific risk be diversified away by investing in both Molecular Partners and Newron Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Molecular Partners and Newron Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Molecular Partners AG and Newron Pharmaceuticals SpA, you can compare the effects of market volatilities on Molecular Partners and Newron Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Molecular Partners with a short position of Newron Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Molecular Partners and Newron Pharmaceuticals.
Diversification Opportunities for Molecular Partners and Newron Pharmaceuticals
0.29 | Correlation Coefficient |
Modest diversification
The 3 months correlation between Molecular and Newron is 0.29. Overlapping area represents the amount of risk that can be diversified away by holding Molecular Partners AG and Newron Pharmaceuticals SpA in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Newron Pharmaceuticals and Molecular Partners is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Molecular Partners AG are associated (or correlated) with Newron Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Newron Pharmaceuticals has no effect on the direction of Molecular Partners i.e., Molecular Partners and Newron Pharmaceuticals go up and down completely randomly.
Pair Corralation between Molecular Partners and Newron Pharmaceuticals
Assuming the 90 days trading horizon Molecular Partners AG is expected to generate 2.26 times more return on investment than Newron Pharmaceuticals. However, Molecular Partners is 2.26 times more volatile than Newron Pharmaceuticals SpA. It trades about -0.08 of its potential returns per unit of risk. Newron Pharmaceuticals SpA is currently generating about -0.32 per unit of risk. If you would invest 552.00 in Molecular Partners AG on August 25, 2024 and sell it today you would lose (67.00) from holding Molecular Partners AG or give up 12.14% of portfolio value over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Very Weak |
| Accuracy | 95.65% |
| Values | Daily Returns |
Molecular Partners AG vs. Newron Pharmaceuticals SpA
Performance |
| Timeline |
| Molecular Partners |
| Newron Pharmaceuticals |
Molecular Partners and Newron Pharmaceuticals Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Molecular Partners and Newron Pharmaceuticals
The main advantage of trading using opposite Molecular Partners and Newron Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Molecular Partners position performs unexpectedly, Newron Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Newron Pharmaceuticals will offset losses from the drop in Newron Pharmaceuticals' long position.| Molecular Partners vs. Idorsia | Molecular Partners vs. Basilea Pharmaceutica AG | Molecular Partners vs. Santhera Pharmaceuticals Holding | Molecular Partners vs. Evolva Holding SA |
| Newron Pharmaceuticals vs. Santhera Pharmaceuticals Holding | Newron Pharmaceuticals vs. Basilea Pharmaceutica AG | Newron Pharmaceuticals vs. Addex Therapeutics | Newron Pharmaceuticals vs. Evolva Holding SA |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Other Complementary Tools
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments |